For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 10,645,222 | 10,867,983 | 10,454,160 | |
| General and administrative | 4,682,495 | 4,505,406 | 4,296,417 | |
| Amortization of intangible asset | 7,317 | 7,317 | 7,317 | |
| Total operating expenses | 15,335,034 | 15,380,706 | 14,757,894 | |
| Loss from operations | -15,335,034 | -15,380,706 | -14,757,894 | |
| Interest income | 1,360,404 | 415,831 | 324,013 | |
| Other income, net | 513,735 | 0 | 0 | |
| Net loss | -13,460,895 | -14,964,875 | -14,433,881 | |
| Unrealized loss from marketable securities | -322,337 | 0 | 0 | |
| Comprehensive loss | -13,783,232 | -14,964,875 | -14,433,881 | |
| Basic EPS | -0.21 | -0.38 | -0.4 | |
| Diluted EPS | -0.21 | -0.38 | -0.4 | |
| Basic Average Shares | 64,658,809 | 39,670,095 | 35,985,878 | |
| Diluted Average Shares | 64,658,809 | 39,670,095 | 35,985,878 | |
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)